Related Experiment Video
Updated: May 16, 2026
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Ginsenoside Rh2 mediates changes in the microRNA expression profile of human non-small cell lung cancer A549 cells
In-Sook An1, Sungkwan An, Ku Jung Kwon
1Korea Institute for Skin and Clinical Sciences, Seoul 143-701, Republic of Korea.
Abstract:
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer insensitive to chemotherapy. Efforts are, therefore, directed toward understanding the molecular mechanisms of chemotherapy insensitivity and the development of new anticancer drugs. Ginsenoside Rh2, one of the components in ginseng saponin, has been shown to have anti-proliferative effect on human NSCLC cells and is being studied as a therapeutic drug for NSCLC. microRNAs (miRNAs) are small, non-coding RNA molecules that play a key role in cancer progression and prevention. However, the miRNA portrait of ginsenoside Rh2-treated NSCLC cells has not yet been studied. In this study, we identified a unique set of changes in the miRNA expression profile in response to Rh2 treatment in the human NSCLC cell line A549. Using miRNA microarray analysis, we identified 44 and 24 miRNAs displaying changes in expression greater than 2-fold in Rh2-treated A549 cells. In addition, using an miRNA target prediction program, we discovered that these miRNAs are predicted to have several target genes related to angiogenesis, apoptosis, chromatic modification, cell proliferation and differentiation. Thus, these results may assist in the better understanding of the anticancer mechanism of Rh2 in NSCLC.
Insights
Ginsenoside Rh2 alters microRNA expression in non-small cell lung cancer (NSCLC) cells. This study identifies specific microRNAs and their potential targets, offering insights into Rh2
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) exhibits resistance to conventional chemotherapy.
- Ginsenoside Rh2, a ginseng saponin derivative, demonstrates anti-proliferative effects on NSCLC cells and is under investigation as a potential therapeutic agent.
- MicroRNAs (miRNAs) are crucial regulators of gene expression implicated in cancer development and progression.
Purpose of the Study:
- To investigate the impact of Ginsenoside Rh2 on the microRNA expression profile in human NSCLC cells.
- To identify specific microRNAs affected by Rh2 treatment.
- To predict the target genes of these differentially expressed miRNAs and elucidate the anticancer mechanisms of Rh2.
Main Methods:
- Utilized miRNA microarray analysis to profile miRNA expression in A549 NSCLC cells treated with Ginsenoside Rh2.
- Identified microRNAs with significant expression changes (greater than 2-fold).
- Employed miRNA target prediction software to identify potential target genes associated with key cellular processes.
Main Results:
- Identified 44 upregulated and 24 downregulated miRNAs in Rh2-treated A549 NSCLC cells.
- Predicted target genes of these miRNAs are involved in critical pathways including angiogenesis, apoptosis, chromatin modification, cell proliferation, and differentiation.
- Revealed a distinct miRNA expression signature induced by Rh2 treatment in NSCLC cells.
Conclusions:
- Ginsenoside Rh2 significantly alters the miRNA expression profile in non-small cell lung cancer cells.
- The identified miRNAs and their predicted targets provide insights into the molecular mechanisms underlying Rh2's anti-cancer effects.
- These findings contribute to understanding Rh2's therapeutic potential for NSCLC and may guide the development of novel treatment strategies.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs